Madrigal Pharmaceuticals (NASDAQ: MDGL) saw its stock surge 6.34% in pre-market trading following the release of its third-quarter 2025 financial results, which showcased significant revenue growth driven by strong demand for its drug Rezdiffra.

The company reported Q3 product revenue of $287.26 million, representing a substantial 362.03% increase compared to the same period last year. This impressive growth was primarily attributed to the increasing demand for Rezdiffra, Madrigal's flagship product. Despite the revenue surge, the company still reported a net loss of $114.19 million, or $5.08 per share, which was wider than analyst estimates.

In addition to the strong financial performance, Madrigal announced a global licensing agreement with CSPC Pharma for an oral GLP-1 receptor agonist, signaling potential future growth opportunities. The company also highlighted its recent launch of Rezdiffra in Germany following European Commission approval, further expanding its market reach. With Rezdiffra's patent protection extending to 2045 and plans to initiate clinical trials for the oral GLP-1 in the first half of 2026, investors appear optimistic about Madrigal's long-term prospects in the thriving biotech sector.